Affibody AB
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
14
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 25, 2026 · next Dec 18
- 1 fee due Jan 30, 2027The maintenance fee for New Polypeptide (US 10,364,280) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due May 17, 2027The maintenance fee for Polypeptide derived from protein A and able to bind PDGF (US 9,187,535) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Jun 15, 2027The maintenance fee for Polypeptides (US 9,211,344) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
- 2 fees due Aug 11 to 18, 2027 · next Aug 11
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,598,113 | Polypeptides In force · From the USPTO record | In force | From the USPTO record | |
| US 9,107,965 | Polypeptides In force · From the USPTO record | In force | From the USPTO record | |
| US 7,993,650 | Polypeptides having binding affinity for HER2 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,118,949 | Compositions, methods and uses In force · From the USPTO record | In force | From the USPTO record | |
| US 8,883,120 | Polypeptides having affinity for HER2 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,642,743 | Method For Reducing The Immune Response To a Biologically Active Protein In force · High confidence | In force | High confidence | |
| US 8,247,375 | Polypeptides In force · From the USPTO record | In force | From the USPTO record | |
| US 8,501,909 | Polypeptides having affinity for HER2 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,556,933 | Polypeptide libraries with a predetermined scaffold In force · From the USPTO record | In force | From the USPTO record | |
| US 9,187,535 | Polypeptide derived from protein A and able to bind PDGF In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 34: 4 patents in force now held by others · 6 lapsed for an unpaid fee · 5 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 7 abandoned · 7 no status recorded